As the global burden of thrombotic diseases grows, with the global
urokinase raw material market valued at USD 84.47 million in 2025 and projected
to reach USD 123 million by 2032 at a CAGR of 5.1%,
pharmaceutical partners, hospitals, and healthcare providers worldwide are
seeking a trusted Urokinase Manufacturer that delivers uncompromising quality,
strict safety standards, and tailored cross-border solutions. Urokinase, a
serine protease derived from human urine, is an indispensable
thrombolytic agent used to dissolve blood clots in life-threatening conditions
such as pulmonary embolism, deep vein thrombosis, and catheter occlusion. Kangyuan, a leading biopharmaceutical
Urokinase Manufacturer with over 20 years of experience in urinary-derived APIs, stands out with its dual viral inactivation technology and
high-molecular weight control, addressing industry pain points of viral safety
risks and inconsistent molecular purity while serving global markets across
North America, Europe, Asia-Pacific, and beyond.
What distinguishes Kangyuan as a premier Urokinase Manufacturer is its
proprietary dual viral inactivation process and strict high-molecular weight
control—innovations that redefine safety and efficacy standards for urokinase
production. Unlike conventional manufacturers relying on single-step viral
inactivation, Kangyuan integrates two complementary methods:
60℃ dry heat treatment for 10 hours (as required by ChP)and ultraviolet irradiation, ensuring complete
elimination of potential pathogens while preserving the enzyme’s native
bioactivity. Additionally, we implement precise chromatographic separation to
maintain high-molecular weight urokinase content of no less than 90%, achieving a specific activity of ≥120,000
IU/mg protein and purity exceeding 99% (HPLC). This ensures our urokinase
delivers consistent thrombolytic efficacy, reduces bleeding risks, and fully
complies with USP, EP, and ChP pharmacopeial standards.
As a global Urokinase Manufacturer, Kangyuan excels in navigating complex
regional regulatory frameworks, a critical advantage for partners seeking
seamless market access. In North America, our urokinase complies with FDA
guidelines, supporting Biologics License Application (BLA) and adhering to
strict cGMP requirements, with comprehensive documentation to
address the region’s focus on viral safety and raw material traceability. In
Europe, we meet EMA regulations, leveraging the centralized approval procedureand providing full supply chain traceability
to ensure compliance, making our product a preferred choice for hospitals
requiring reliable catheter occlusion and peripheral artery thrombosis treatment. In Asia-Pacific, the largest urokinase market, we leverage
our stable raw material supply—collecting 50 tons of qualified male urine daily—to offer competitive pricing, catering to regional healthcare
budgets while maintaining NMPA compliance.
Kangyuan’s competitive edge as a Urokinase Manufacturer lies in its stable
supply chain, scalable capacity, and customer-centric service. Our GMP-certified
facilities boast a monthly production capacity of 15,000 MIU,
capable of fulfilling both small-batch R&D orders and large-scale commercial
supply. We source raw materials from a standardized collection network, ensuring
high-quality human urine to maintain product consistency. Every batch undergoes rigorous testing, including viral
inactivation verification, molecular weight analysis, and specific activity
validation, guaranteeing safety and
efficacy. We also offer flexible customization options, including different
potency specifications and lyophilized powder formulations,
tailored to regional clinical preferences such as catheter-directed thrombolysis
and systemic infusion.
As the global urokinase market evolves toward more specialized clinical
applications, Kangyuan remains at the forefront of
innovation. Our ongoing R&D focuses on optimizing dual viral inactivation
technology and enhancing production efficiency, while expanding regulatory
compliance to cover emerging markets in Latin America and the Middle East.
Backed by decades of expertise in urinary-derived APIs, GMP certification, and a
global presence in 40+ countries, Kangyuan has become a trusted Urokinase
Manufacturer for pharmaceutical companies, hospitals, and healthcare providers
worldwide.
Ready to source high-purity, virus-safe urokinase with reliable supply?
Contact Kangyuan today to discuss your specific requirements, request samples,
or learn how our dual viral inactivation technology can elevate your
thrombolytic products and support your success in the global market.